Saturday, May 28, 2022
  • About Us
  • ImagiNATION
  • Adverts
  • Rate Card
  • Contact Us
The Nation Online
Advertisement
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation
No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation
No Result
View All Result
No Result
View All Result
Home News National News

New malaria drug in Malaria

by Staff Writer
04/02/2013
in National News
2 min read
0
Share on FacebookShare on TwitterShare on WhatsAppShare on LinkedinLinkedinShare via Email

Beijing Holley Cotec, a Chinese pharmaceutical company, on Friday launched a new brand of drugs to fight malaria in Malawi, offering a three-day, one-dose-a-day therapy for patients.

Duo-cotecxin, the company’s anti-malaria drug introduced at Sunbird Capital in Malawi’s capital, Lilongwe, was launched by Pharmacy, Medicine & Poisons Board (PMPB) chairperson Henry Chipeta during a function also attended by Tanzania High Commissioner Patrick Tsere.

The drug is being distributed by Euro Pharmaceuticals in the country.

“I would like to thank the Holley-Cotec pharmaceutical company for introducing duo-cotecxin to Malawi for the treatment of malaria,” said Chipeta.

He advised the company to stick to professionalism to avoid an influx of counterfeit supplies.

The new drug, as one of the Artemisinin Combination Therapies (ACTs) advised by the World Health Organisation (WHO), has come to Malawi following successful launch in Tanzania and 30 other countries, according to the company’s managing director Jacky Zhou.

Holley-Cotec marketing manager Majebele Kissandu claimed the drug has 98 percent efficacy and has minimum side effects unlike other anti-malaria drugs.

In Malawi, malaria is a big problem and a leading cause of illness and death among under-five children and pregnant women, according to a Unicef brochure which adds that six million illnesses are reported every year, 85 percent of them caused by plasmodium falcparum.

Previous Post

Govt endorses Kinnah’s firing, redeploy panel

Next Post

Committee queries K1.3bn maize gap in Malawi

Related Posts

RBM headquarters in Lilongwe
Front Page

RBM justifies devaluation stance

May 28, 2022
Kumchulesi: Financing options are available
National News

NPC gears up to empower young entrepreneurs for MW2063 results

May 28, 2022
Bingu’s residence named Casablanca Manor 
at his Ndata Farm in Thyoo
Front Page

ACB sleeps on Bingu’s wealth investigation

May 28, 2022
Next Post

Committee queries K1.3bn maize gap in Malawi

Opinions and Columns

Off the Shelf

Poor timing of Aggreko decommissioning now hurting

May 28, 2022
My Diary

Corruption as an elephant

May 28, 2022
Business Unpacked

Tame egos, take risks to grow economy

May 26, 2022
People’s Tribunal

What was that press briefing all about?

May 22, 2022

Trending Stories

  • His case heard in UK court: Sattar

    Acb explains Sattar miss

    0 shares
    Share 0 Tweet 0
  • Kwacha gets 25% weaker

    0 shares
    Share 0 Tweet 0
  • AmaZulu complete signing Gaba

    0 shares
    Share 0 Tweet 0
  • Conforzi to invest K8.2bn in PPP venture

    0 shares
    Share 0 Tweet 0
  • Gone but still in our midst

    0 shares
    Share 0 Tweet 0

Malawi-Music.com Top10

  • Values
  • Our Philosophy
  • Editorial policy
  • Advertising Policy
  • Code of Conduct
  • Plagiarism disclaimer
  • Disclaimer
  • Privacy Policy
  • Terms of use

© 2022 Nation Publications Limited. All Rights Reserved.

No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation

© 2020 Nation Publications Limited. All Rights Reserved.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.